SOX2 and glioblastoma: Although long term GBM cell lines have their limitations since they might differ in some aspects from primary tumor cells, caution is advised when setting up treatment strategies targeting SOX2 in glioblastoma patients, since a decrease in invasion proteolysis-dependent migration capacity might to some extent be compensated by a switch to an amoeboid-like migration which might affect survival of patients.